Natera Inc., a cell-free DNA and precision medicine company, has acquired Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection, in an all-stock transaction consisting of a $275 million up front with an additional $175 million in earnouts tied to the achievement of revenue- and reimbursement-based milestones. “This acquisition reinforces Natera’s position at the forefront of precision oncology,” said Steve Chapman, CEO of Natera. “Foresight’s phased vari...